Merck’s Experimental Drug Meets Key Goal in Eye Trial
NEW YORK: (News Desk) - US pharmaceutical giant Merck said its experimental drug Remigromig met the primary goal of a 52-week clinical trial involving patients with diabetic macular edema, a diabetes-related eye condition that can impair…